Matching articles for "Symproic"
Opioids for Pain
The Medical Letter on Drugs and Therapeutics • December 12, 2022; (Issue 1665)
A new CDC guideline for prescribing opioids for pain
recently became available. Nonopioid drugs for pain
were reviewed in a previous...
A new CDC guideline for prescribing opioids for pain
recently became available. Nonopioid drugs for pain
were reviewed in a previous issue.
Opioids for Pain
The Medical Letter on Drugs and Therapeutics • April 9, 2018; (Issue 1544)
Use of nonopioid drugs for pain was reviewed in a
previous issue. For many types of moderate to severe acute pain, acetaminophen and/or an NSAID may be as effective as an opioid. Immediate-release formulations...
Use of nonopioid drugs for pain was reviewed in a
previous issue. For many types of moderate to severe acute pain, acetaminophen and/or an NSAID may be as effective as an opioid. Immediate-release formulations of full opioid agonists should generally be used for acute pain that is severe enough to require treatment with an opioid. Use of extended-release or long-acting opioid formulations initially and treatment durations >1 week have been associated with an increased risk of unintended long-term use.
Naldemedine (Symproic) for Opioid-Induced Constipation
The Medical Letter on Drugs and Therapeutics • December 4, 2017; (Issue 1535)
The FDA has approved the opioid receptor antagonist
naldemedine (Symproic – Shionogi) for treatment
of opioid-induced constipation (OIC) in adults with
chronic noncancer pain. Naldemedine is the third...
The FDA has approved the opioid receptor antagonist
naldemedine (Symproic – Shionogi) for treatment
of opioid-induced constipation (OIC) in adults with
chronic noncancer pain. Naldemedine is the third oral
peripherally-acting mu-opioid receptor antagonist
(PAMORA) to be approved for this indication; naloxegol
(Movantik) and methylnaltrexone (Relistor) were
approved earlier.